-

10:07:20 PM

BNTX Stock News

BNTX - BioNTech SE

06/29/22 4:45 PM

NYSE, Nasdaq : PFE, BNTX

covid-19

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

Pfizer Inc. and BioNTech SE today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses. “As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that may...

RHEA-AI

neutral

06/29/22 4:45 PM

Nasdaq : BNTX

covid-19

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses NEW YORK and MAINZ, GERMANY, JUNE 29, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply

RHEA-AI

neutral

06/25/22 10:02 AM

Nasdaq : BNTX

covid-19

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios

RHEA-AI

neutral

06/25/22 10:00 AM

NYSE, Nasdaq : PFE, BNTX

covid-19

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

Pfizer Inc. and BioNTech SE today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1...

RHEA-AI

neutral

06/23/22 11:00 AM

Nasdaq : BNTX

BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer

First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency for enhanced regulatory support facilitating the clinical development of the investigational cell therapy candidate BNT211 in the third- or later-line setting in patients with heavily

RHEA-AI

positive

06/23/22 6:00 AM

Nasdaq : BNTX

BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa

Breaking of Ground for BioNTech’s initial African modular mRNA manufacturing facility in Kigali, Rwanda; delivery of first container modules planned for end of 2022 On invitation by H.E. President Paul Kagame of Rwanda, Heads of State and Government from Africa and around the world, highest

RHEA-AI

neutral

06/20/22 11:30 AM

Nasdaq : BNTX

conferences

BioNTech to Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations

BioNTech SE (Nasdaq: BNTX, “BioNTech” or the "Company”) will host the first edition of the Company’s Innovation Series on Wednesday, June 29 th, 2022. The virtual event will provide an update on BioNTech’s clinical progress across its pipeline and

RHEA-AI

neutral

06/17/22 9:24 AM

NYSE, Nasdaq : PFE, BNTX

covid-19

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

Pfizer Inc. and BioNTech SE today announced the U.S. Food and Drug Administration granted emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine as a three 3- µg dose series for children 6 months through 4 years of age. We know many parents in the U.S. have been eagerly awaiting an authorized vaccine for their children...

RHEA-AI

positive

06/17/22 9:22 AM

Nasdaq : BNTX

covid-19

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile s imilar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now

RHEA-AI

very positive

06/09/22 8:31 AM

Nasdaq : BNTX

BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa

MAINZ, Germany, June 9, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) will welcome its African partners for the first time on the African continent and provide an update on the joint establishment of mRNA manufacturing facilities and vaccine development plans. The event will

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next